Research Shows Healthcare Cost Growth, Not Insurer Profits, Driving Premium Increases
A new study analyzing commercial insurance data from 2011 to 2024 found that 91% of the 78.4% increase in average premiums was driven by rising underlying healthcare costs, while only 9% was attributable to insurer markup and administrative expenses. Insurer profit margins actually declined during this period, falling from 18.6% to 14.9% by 2024, suggesting that efforts to control healthcare costs should focus on addressing underlying medical spending rather than targeting insurance company profits. The research indicates that meaningful healthcare reform requires attention to price controls, primary care expansion, and care management strategies rather than insurer accountability alone.
Between 2011 and 2024, commercial insurance premiums climbed substantially, yet the research reveals that this growth stems overwhelmingly from the underlying medical services themselves rather than insurance intermediaries. The data shows that while premiums rose by over $3,100 per enrollee during this 13-year span, healthcare spending increases accounted for nearly all of that rise. Simultaneously, insurers' ability to retain earnings as profit actually contracted, with their financial cushion shrinking by nearly 4 percentage points, constrained partly by regulatory requirements governing what portion of premium revenue they must allocate to actual medical claims.
The findings suggest that policymakers focused solely on reining in insurer revenues may be addressing symptoms rather than root causes. If premium affordability is the goal, the data points toward interventions targeting pharmaceutical pricing, service delivery models, and care coordination—areas where cost variation among providers remains significant and largely uncontrolled.
This research could influence how lawmakers approach healthcare affordability debates, potentially redirecting scrutiny from insurance company business practices toward physician pricing, hospital charges, and pharmaceutical costs. Consumers frustrated by premium increases may recalibrate their understanding of cost drivers. However, stakeholders have vested interests in different reform approaches, meaning the study's findings may face contested interpretation. The net effect on actual policy depends on whether its conclusions gain traction among elected officials and whether proposed structural reforms prove politically feasible.